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ABSTRACT
Introduction: Mortality prediction scores are widely
used in intensive care units (ICUs) and in research, but
their predictive value deteriorates as scores age.
Existing mortality prediction scores are imprecise and
complex, which increases the risk of missing data and
decreases the applicability bedside in daily clinical
practice. We propose the development and validation of
a new, simple and updated clinical prediction rule: the
Simplified Mortality Score for use in the Intensive Care
Unit (SMS-ICU).
Methods and analysis: During the first phase of the
study, we will develop and internally validate a clinical
prediction rule that predicts 90-day mortality on ICU
admission. The development sample will comprise
4247 adult critically ill patients acutely admitted to the
ICU, enrolled in 5 contemporary high-quality ICU
studies/trials. The score will be developed using binary
logistic regression analysis with backward stepwise
elimination of candidate variables, and subsequently be
converted into a point-based clinical prediction rule.
The general performance, discrimination and
calibration of the score will be evaluated, and the score
will be internally validated using bootstrapping. During
the second phase of the study, the score will be
externally validated in a fully independent sample
consisting of 3350 patients included in the ongoing
Stress Ulcer Prophylaxis in the Intensive Care Unit trial.
We will compare the performance of the SMS-ICU to
that of existing scores.
Ethics and dissemination: We will use data from
patients enrolled in studies/trials already approved by
the relevant ethical committees and this study requires
no further permissions. The results will be reported in
accordance with the Transparent Reporting of
multivariate prediction models for Individual Prognosis
Or Diagnosis (TRIPOD) statement, and submitted to a
peer-reviewed journal.
INTRODUCTION
This protocol describes the development of a
new clinical prediction rule for use in the
intensive care unit (ICU): the Simpliﬁed
Mortality Score for use in the Intensive Care
Unit (SMS-ICU). The protocol describes the
derivation and internal validation of the
score (phase 1) and the external validation
(phase 2). An overview of the steps
described in the protocol is provided in
ﬁgure 1. This manuscript has been prepared
according to the Transparent Reporting of
multivariate prediction models for Individual
Prognosis Or Diagnosis (TRIPOD) state-
ment1 (checklist included as online
supplementary ﬁle 1).
Strengths and limitations of this study
▪ Publication of a protocol for an observational
study reduces risk of bias and increases
transparency.
▪ Use of prospectively recorded data from inter-
national, contemporary, high-quality studies/trials
increase data validity and generalisability.
▪ Use of 90-day mortality as outcome measure will
not be affected by intensive care unit (ICU)/hos-
pital discharge practices, as compared with
in-ICU or in-hospital mortality.
▪ The original study/trial databases comprise a
limited number of variables because of the prag-
matic designs.
▪ The included participants, interventions and
comparators assessed in the original studies/
trials differ slightly, but all patients were adults
acutely admitted to an ICU.
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Background
Severity scores are used in ICUs to assess disease severity,
make prognostic predictions, compare the performance
of ICUs and in research.2–4 The performance of severity
scores deteriorates over time,5 6 and one of the most
widely used mortality prediction scores, the Simpliﬁed
Acute Physiology Score (SAPS) II, is more than 20 years
old.7
Most mortality prediction scores include many differ-
ent variables and are thus very complex. This limits
clinical use and increases the risk of missing data which
is a common challenge when used in research.8–10
More complex scores do not necessarily perform better,
and the performance of the newer and more complex
SAPS 311 is comparable to that of SAPS II.12–16 The
Sequential Organ Failure Assessment (SOFA) score17 is
somewhat simpler than SAPS II, and although it was
not developed for this purpose, it appears to be only
slightly inferior to SAPS II at predicting mortality.18 19
Recently, Dólera-Moreno et al20 presented a simple
score that predicts in-ICU mortality, based on data from
a single ICU.
A simple and contemporary clinical prediction rule
using few readily available variables developed on data
from multiple centres and using 90-day mortality as the
outcome measure, could prove a valuable tool for use at
the bedside in daily clinical practice in the ICU and in
research.
Hypothesis and aim
We hypothesise that a new, simple and clinically useful
mortality prediction score for use in the ICU can be
developed and used to reliably estimate the risk of mor-
tality within 90 days of admission to the ICU.
Additionally, we hypothesise that such a score will
perform as well as existing and more complex scores (ie,
SAPS II).
Accordingly, we aim to develop and validate a simple
clinical prediction rule—the SMS-ICU—which can be
used at the bedside on ICU admission to reliably esti-
mate the risk of mortality 90 days after ICU admission.
METHODS AND ANALYSIS
As described by Labarère et al,21 the development of
clinical prediction rules encompasses three consecutive
phases: derivation, external validation and impact ana-
lysis. This protocol describes the derivation and internal
validation (phase 1) and the external validation (phase
2) of the score. If the score performs satisfactory during
the validations, we will encourage use of the score in
everyday clinical practice and subsequently conduct an
impact analysis the details of which will be planned later.
PHASE 1: DEVELOPMENT AND INTERNAL VALIDATION
In the ﬁrst phase of the project, a mortality prediction
model will be developed, evaluated and converted into a
simple score that can be used at the bedside.
Subsequently, the score will be internally validated.
Study design
An international cohort study comprising patients from
the Scandinavian Starch for Severe Sepsis/Septic Shock
(6S) trial,8 the Transfusion Requirements In Septic
Shock (TRISS) trial,9 the Conservative versus Liberal
Approach to ﬂuid therapy of Septic Shock in Intensive
Care (CLASSIC) trial,22 the Stress Ulcer Prophylaxis in
the Intensive Care Unit (SUP-ICU) inception cohort
study10 and the Agents Intervening against Delirium in
Intensive Care Unit (AID-ICU) inception cohort study.23
Study participants
All 4247 patients included in the 6S (n=798; 26 ICUs in
4 countries),8 TRISS (n=998; 32 ICUs in 4 countries)9
Figure 1 Flow chart illustrating
the major steps in the
development and validation of the
score as described in this
protocol. SAPS, Simplified Acute
Physiology Score; SMS-ICU,
Simplified Mortality Score for the
Intensive Care Unit; SOFA,
Sequential Organ Failure
Assessment.
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and CLASSIC trials (n=151; 9 ICUs in 2 countries),22
and in the SUP-ICU (n=1034; 97 ICUs in 11 countries)10
and AID-ICU (n=1266; 99 ICUs in 13 countries)23 incep-
tion cohort studies.
The sample consists of adult (≥18 years) critically ill
patients acutely admitted to ICUs in university and non-
university hospitals. Enrolment of patients in the devel-
opment sample took place between 23 December 2009
and 30 June 2016. Data collection for the last included
patients in the development sample has recently con-
cluded and data are currently undergoing validation.
Speciﬁc inclusion and exclusion criteria and enrolment
dates for the studies are listed in online supplementary
ﬁle 2.
Data sources
A combined database comprising data from the 6S,
TRISS and CLASSIC trial databases, and from the
SUP-ICU and AID-ICU inception cohort databases.
Variables
The outcome measure will be 90-day mortality (90 days
following inclusion in the trials/studies). Adverse prog-
nostic factors for 90-day mortality will be assessed.
Table 1 contains a complete list of the variables that
will be included in the combined database. All variables
are known potential predictors of 90-day mortality, and
all variables are registered in the 6S, TRISS, CLASSIC
and SUP-ICU trials and in the SUP-ICU and AID-ICU
inception cohort studies. For the selection of candidate
variables from this list, see the Statistics section.
Owing to the hard outcome measure, no actions will
be taken to blind investigators to the outcome or pre-
dictor variables.
Statistics
Baseline and clinical characteristics for all patients in
the combined database will be presented as medians
with IQRs for continuous data, and numbers (%) for
categorical data stratiﬁed by 90-day mortality.25
Differences will be assessed by Mann-Whitney U test and
χ2 test as appropriate.
The score will be developed in ﬁve steps:
1. Candidate predictor variables will be selected;
2. Candidate variables with more than 25% missing data
will be excluded;
3. For the remaining variables, multiple imputations will
be performed for the missing values;
4. A logistic regression model with 90-day mortality as
the outcome of interest will be developed;
5. The logistic regression model will be converted into a
clinical prediction rule.26
Candidate variables
Candidate variables for the score will be selected based
on three criteria:
1. Variables have to be potentially predictive of mortality
based on existing literature;
2. Variables have to be readily available on ICU admis-
sion in everyday clinical practice;
3. Variables have to be present in the 6S, TRISS and
CLASSIC trials databases, in the SUP-ICU and AID-
ICU inception cohort study databases, and in the
SUP-ICU trial database24 (for external validation,
phase 2).
A complete list of candidate variables can be found in
table 1.
Table 1 Variables studied
Variable Data format
Demographic/anamnestic variables
Age Years (continuous)
Gender Male/female (binary)
Admission type Surgical/medical
(binary)
Hospital length of stay prior to
ICU admission
Days (continuous)
Comorbidity variables
Metastatic cancer Yes/no (binary)
Haematological malignancy Yes/no (binary)
AIDS Yes/no (binary)
Physiological variables
Lowest heart rate* Beats per minute
(continuous)
Highest heart rate* Beats per minute
(continuous)
Lowest systolic blood pressure* mm Hg (continuous)
Highest systolic blood pressure* mm Hg (continuous)
Body temperature ≥39° C* Yes/no (binary)
Biochemical variables
Lowest white cell count* 109/L (continuous)
Highest white cell count* 109/L (continuous)
Lowest potassium* mmol/L (continuous)
Highest potassium* mmol/L (continuous)
Lowest sodium* mmol/L (continuous)
Highest sodium* mmol/L (continuous)
Lowest bicarbonate* mmol/L (continuous)
Treatment variables
Use of vasopressors/inotropes† Yes/no (binary)
Use of mechanical ventilation† Yes/no (binary)
Use of renal replacement
therapy†
Yes/no (binary)
Outcome variable
Vital status 90 days after
inclusion
Dead/alive (binary)
For detailed definitions of the variables, please refer to the original
publications/protocols.8–10 22–24
All variables registered at inclusion in the different studies/trials
except where otherwise noted.
*Worst value registered during the 24 hours prior to inclusion (6S,
TRISS, CLASSIC and SUP-ICU trials) or during the first 24 hours
in the ICU (SUP-ICU and AID-ICU inception cohorts).
†Treatment initiated or continued on the day of inclusion.
6S, Scandinavian Starch for Severe Sepsis/Septic Shock;
AID-ICU, Agents Intervening against Delirium in Intensive Care
Unit; ICU, intensive care unit; CLASSIC, Conservative versus
Liberal Approach to fluid therapy of Septic Shock in Intensive
Care; SUP-ICU, Stress Ulcer Prophylaxis in the Intensive Care
Unit; TRISS, Transfusion Requirements In Septic Shock.
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Missing data and multiple imputation
Candidate variables with more than 25% missing data will
be excluded. As data are unlikely to be missing completely
at random, multiple imputations for the missing values for
the remaining candidate variables will be performed.27 28
Multiple imputations will be performed with the fully
conditional speciﬁcation method with 10 imputed data
sets and with the inclusion of the outcome measure and
the candidate variables remaining after variables with
more than 25% missing data having been excluded.
Multiple imputations for missing outcome data will
not be performed and patients with missing 90-day mor-
tality data will be excluded from all analyses.27
Logistic regression modelling
Binary logistic regression analysis including the selected
candidate variables as independent co-variates and
90-day mortality as the dependent variable will be
performed. Continuous co-variates will not be converted
to categorical co-variates during this process.
Transformation to address possible non-linearity will be
considered. Backward stepwise elimination modelling
will be used based on the p values for the individual vari-
ables obtained from the likelihood ratio test.21 To ensure
that the score is suitable for use at the bedside, we will
aim to limit the number of variables to ensure simplicity
and clinical relevance. In order to do this, a prespeciﬁed
signiﬁcance threshold for the elimination of variables has
not been set. Results will be presented as adjusted ORs
with 95% CIs and regression coefﬁcients (β-values).
Conversion into the clinical prediction rule
The logistic regression model will be converted into a
clinical prediction rule—the SMS-ICU—by transforming
the individual parameter estimates (log(OR)/β-values)
of the model into weights (points) according to the
method used in the Framingham Heart Study.29
Continuous variables will be converted to ordinal cat-
egorical variables based on clinically meaningful thresh-
olds and the lowest adjusted OR/β-value will be used as
reference for each ordinal variable. An increasing
amount of points will then be assigned according to
equivalently spaced adjusted OR/β-values.29 The same
method will be used for dichotomous variables.29 30 A
logistic regression analysis with the total score as the
only independent variable and 90-day mortality as the
dependent variable will be conducted, and the full
regression model will be presented.
Evaluation of the score
Predicted 90-day mortality risks for the different scores
along with sensitivity, speciﬁcity and observed 90-day
mortality in the full derivation sample will be presented.
The score will be evaluated using model diagnostics.
The overall predictive performance of the score will be
evaluated using Nagelkerke’s R2 for binary exposure,31
which refers to the proportion of variation explained by
the model. Discrimination, which refers to the score’s
ability to distinguish patients that die from patients that
live, will be assessed using the area under the receiver
operating characteristics curve (AUC).32 Finally, calibra-
tion will be assessed as recommended in the litera-
ture,21 33 via calibration plots and intercept α and slope
β from the regression of the binary outcome (90-day
mortality) on the predicted values,34 supplemented by
the Hosmer-Lemeshow goodness-of-ﬁt Ĉ-statistic.35
Internal validation
The score will be internally validated using bootstrap-
ping.21 The principle of bootstrapping is to sample from
the empirical distribution from which the data origi-
nated (ie, sampling with replacement from the observed
data).26 36
The same performance measures will be used during
the internal validation process as during the evaluation
process, and optimism-corrected performance estimates
will be presented.21
Sensitivity analysis
The development sample will contain data from the ran-
domised 6S, TRISS and CLASSIC trials. In the TRISS and
CLASSIC trials, no statistically signiﬁcant differences in
90-day mortality was observed between the two treatment
groups;9 22 however, in the 6S trial, mortality was increased
in the group allocated to hydroxyethyl starch (HES) com-
pared with the group allocated to Ringer’s acetate.8
Consequently, a sensitivity analysis with removal of the
patients allocated to HES (n=398) will be conducted.
Analyses will be conducted using SAS V.9.4 or newer
(SAS Institute, Cary, North Carolina, USA). All statistical
tests will be two-tailed. In general, p values <0.05 will be
considered statistically signiﬁcant and 95% CIs will be
presented where appropriate.
Study size and power
The combined database will contain ∼1500 events of
death within 90 days.
The SUP-ICU cohort, and the CLASSIC, TRISS and 6S
trial databases are static databases and contain 1139
events of death within 90 days. The AID-ICU cohort data-
base will be closed before data are used for the present
study, and subsequently be a static database containing
∼380 events of death within 90 days (number of included
patients: 1266, expected 90-day mortality: 30%). As a rule
of thumb, logistic regression and Cox models should use
at least 10 outcome events per predictor to ensure valid
predictive modelling.37 38 As 22 candidate variables are
evaluated, the combined database will contain enough
events for the model to have sufﬁcient power.
PHASE 2: EXTERNAL VALIDATION
In the second phase of the project, the model will be
externally validated in a fully independent sample.21 For
the external validation phase, we will use the full cohort
of the SUP-ICU trial24 after its completion.
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Study design
A preplanned analysis of data from the SUP-ICU trial.24
Study participants
All patients included in the SUP-ICU trial after the com-
pletion of the trial and 90-day follow-up24 (n≈3350; cur-
rently recruiting in 30 university and non-university
ICUs in ﬁve countries with more to be added). The
SUP-ICU trial includes adult (≥18 years) acutely ill
patients admitted to the ICU. Enrolment started on 4
January 2016 and is expected to conclude by the end of
2017, with follow-up during the ﬁrst half of 2018. Full
inclusion and exclusion criteria are listed in online
supplementary ﬁle 2.
Data sources
The SUP-ICU trial database will be used after comple-
tion of the trial and validation of the database, and will
at this time be a static database.
Statistics
Baseline and clinical characteristics for all patients in
the SUP-ICU trial24 will be stratiﬁed by 90-day mortality
and presented as medians with IQRs for continuous
data, and numbers (%) for categorical data.25
Differences will be assessed by Mann-Whitney U test and
χ2 test as appropriate.
Missing data in the SUP-ICU trial database for the
relevant variables will be handled using multiple imputa-
tions, as recently recommended.39 Multiple imputations
with 10 imputed data sets and inclusion of the outcome
measure and the respective predictor variables included
in each score will be performed.27 28 Patients with
missing outcome data (90-day mortality) will be
excluded from the external validation.27
For the external validation, the same measures of
overall performance, discrimination and calibration will
be used to evaluate the score as in phase 1 (above).
Additionally, the performance of the SMS-ICU will be
compared with that of SAPS II7 and the initial SOFA
score17 in the external validation sample. For SAPS II,
overall performance, discrimination and calibration will
be assessed. For the initial SOFA score, only discrimin-
ation will be assessed as the SOFA score includes no pre-
diction model.17 Discrimination of SMS-ICU, SAPS II
and SOFA (AUCs) will be compared using the method
described by DeLong et al.40
Sensitivity analysis
As we do not yet know if 90-day mortality will differ
between the two groups in the SUP-ICU trial, the exter-
nal validation will be conducted using the full study
population. Two preplanned sensitivity analyses will be
conducted by repeating the analyses in either group.
Analyses will be conducted using SAS V.9.4 or newer
(SAS Institute, Cary, North Carolina, USA). All statistical
tests will be two-tailed. p values <0.05 will be considered
statistically signiﬁcant and 95% CIs will be presented
where appropriate.
Study size and power
Assuming a 25% 90-day mortality rate in the SUP-ICU
trial24 there will be ∼840 deaths during follow-up.
Generally, at least 100 events and 100 non-events are
recommended for external validation studies.21 41 The
external validation sample is comparable in size with the
derivation sample and is thus of sufﬁcient size to evalu-
ate the performance of the score.
STRENGTHS AND LIMITATIONS
Strengths of our study include publication of the proto-
col including a statistical analysis plan prior to develop-
ment and validation of the score. Publication of
protocols of observational studies, including studies
developing and reporting prediction models is currently
not mandatory or common practice. Publication of pro-
tocols is important, as it increases transparency and
decreases the risk of bias, data-driven analyses and post
hoc changes in design.42 Second, both the development
and external validation phases will use contemporary
data from international high-quality studies/trials with
prospective data collection. This increases data quality
and geographical generalisability. Third, our score will
use 90-day mortality as the outcome measure. Existing
scores generally use ICU or in-hospital mortality as
outcome measures; however, score performance is
affected by the choice of outcome43 44 and longer ﬁxed-
time outcome measures are currently recommended.45
Our study has limitations too. First, the selection of
candidate variables is limited by the availability of these
variables across the ﬁve original studies used in the
development phase. These variables, however, have pre-
viously been identiﬁed as predictors of mortality and are
used in existing mortality prediction scores.7 Second,
the inclusion and exclusion criteria in the original
studies differ slightly which may limit generalisability of
the score. However, we believe that the use of ﬁve con-
temporary high-quality studies/trials including less, mod-
erately and severely ill ICU patients (SUP-ICU and
AID-ICU inception cohort studies) and more severely ill
patients (6S, TRISS and CLASSIC trials) ensures that
the score will perform adequately across a large spec-
trum of illness severities in the ICU. Third, missing data
may affect the development and validation of the score,
but this is handled using recommended, contemporary
methods (multiple imputation).27 Finally, the majority of
patients were included in Europe and thus geographical
generalisability may be limited outside Europe.
ETHICS AND DISSEMINATION
Ethics and approvals
The 6S, TRISS, CLASSIC and SUP-ICU trials, and the
SUP-ICU and AID-ICU inception cohort studies have all
been approved by the relevant institutions. Full details
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regarding ethics and approvals can be found in the ori-
ginal papers/protocols.8–10 22–24 No further ethics
approvals for the present study are necessary due to the
non-interventional (observational) design.
The development of the score will in no way affect
patient safety or subject participants to any additional or
increased risks.
All original study databases have been approved and
are maintained according to Danish laws. Anonymised
data sets containing only the relevant variables (table 1)
will be extracted from the original study databases and
used for the present study, and the deposition of these
databases does not require further approvals.
Dissemination
Results will be reported in compliance with the TRIPOD
statement1 and published in an international peer-
reviewed journal and presented at relevant academic
conferences, regardless of the ﬁndings. If the score per-
forms satisfactory during the validations, we will develop
an app, a web calculator and/or a pocket guide to facili-
tate easy calculation of the score at the bedside and
encourage its use in ICUs.
Data will be available on request to the corresponding
author. If required by the publishing journals, data will
be provided with the submitted manuscripts.
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